Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Free Express Shipping on Orders $450+ | Peptide of the Week: Tirzepatide - 10% Off This Week
Cartalax is a short synthetic tripeptide commonly identified as Ala-Glu-Asp, AED or T-31. It is discussed in short peptide bioregulator research, connective tissue models, fibroblast biology, mesenchymal stem cell aging studies, extracellular matrix signaling and cartilage-related experimental frameworks. This 2026 guide explains what Cartalax is, how it is positioned in the short peptide literature, what research areas are most relevant, what evidence limitations exist, how it compares with BPC-157, TB-500, GHK-Cu and AHK-Cu, and what quality, documentation, storage and research-use-only standards matter when evaluating this compound.
Cartalax is a short synthetic tripeptide commonly described as Ala-Glu-Asp, AED or T-31. It is studied in short peptide bioregulator research involving connective tissue, cartilage matrix biology, fibroblast function, mesenchymal stem cell aging models and gene-expression signaling. Cartalax should be described as an emerging research peptide with limited direct clinical evidence, not as a joint treatment, arthritis therapy, cartilage repair drug, anti-aging product or consumer-use compound.
Cartalax belongs to the short peptide bioregulator category. It is usually described as a three-amino-acid peptide with the sequence alanine-glutamic acid-aspartic acid, abbreviated Ala-Glu-Asp or AED. Because it is short, Cartalax is often discussed in the same broader scientific category as other 2 to 4 amino acid bioregulatory peptides, including KED, KE and AEDG.
Cartalax is a tiny peptide made from three amino acids. Researchers study it because short peptides like AED may influence gene-expression patterns, connective tissue cell behavior and extracellular matrix-related pathways in controlled laboratory models.
The most conservative and accurate framing is that Cartalax is an early-stage research peptide. Its strongest evidence context comes from short peptide bioregulator literature, mesenchymal stem cell aging research, fibroblast and connective tissue models, and broader cartilage peptide research. It should not be presented as an established clinical solution for joints, cartilage, arthritis or aging.
Cartalax is a synthetic tripeptide commonly described by the sequence Ala-Glu-Asp. It is part of the broader short peptide bioregulator category, where very small peptide sequences are studied for possible effects on gene expression, cellular aging markers, tissue-specific cell behavior and extracellular matrix-related signaling.
| Feature | Cartalax Detail | Research Interpretation |
|---|---|---|
| Common name | Cartalax | Primary product and research-market name for the compound. |
| Common sequence | Ala-Glu-Asp | Three-amino-acid sequence: alanine, glutamic acid and aspartic acid. |
| Common synonyms | AED, T-31, alanyl-glutamyl-aspartic acid | Useful for identifying the compound across databases and supplier documentation. |
| Compound class | Short synthetic tripeptide | Belongs to the short peptide bioregulator research category. |
| Common CAS reference | 205640-90-0 | Supplier-facing CAS reference commonly associated with Cartalax; researchers should confirm against COA and identity testing. |
| PubChem CID | 87815447 | PubChem compound record for alanyl-glutamyl-aspartic acid. |
| Molecular formula | C12H19N3O8 | Useful for identity review and analytical documentation. |
| Research-use status | Laboratory research only | Not for human consumption, veterinary use, diagnostic use, therapeutic use, joint treatment, cosmetic use or anti-aging use. |
Cartalax mechanism research should be described cautiously. The broader short peptide literature suggests that some 2 to 4 amino acid peptides may influence gene-expression patterns, cellular aging markers and tissue-specific differentiation pathways. For Cartalax specifically, the strongest responsible framing is exploratory and mechanistic.
| Mechanistic Area | Research Role | Why It Matters for Cartalax |
|---|---|---|
| Short peptide bioregulation | Small peptides may influence cellular signaling, gene-expression patterns and tissue-specific cell behavior in experimental systems. | Cartalax is interpreted through the short peptide bioregulator framework. |
| Ala-Glu-Asp sequence | Three-amino-acid sequence used in AED-related research models. | Sequence identity is central to distinguishing Cartalax from AEDG, KED, KE and other short peptides. |
| Gene-expression models | Human mesenchymal stem cell aging research has examined AED effects on genes including IGF1, FOXO1, TERT, TNKS2 and NFκB. | Supports a gene-expression research context, not a clinical outcome claim. |
| Fibroblast biology | Short peptide literature includes research on fibroblast function, senescence markers and extracellular matrix-related pathways. | Relevant to connective tissue models and matrix biology. |
| Cartilage matrix research | Cartilage peptide research often studies chondrocytes, collagen, proteoglycans and extracellular matrix balance. | Provides a mechanistic framework for cartilage-related experimental questions. |
| Evidence gap | Cartalax-specific cartilage repair evidence is much thinner than general cartilage engineering or repair peptide literature. | Requires conservative language and clear limits on claims. |
Cartalax is most relevant to short peptide bioregulator research, mesenchymal stem cell aging studies, fibroblast models, extracellular matrix biology, cartilage pathway research and connective tissue experimental frameworks.
| Research Area | What Is Being Studied | Important Limitation |
|---|---|---|
| Short peptide bioregulation | How 2 to 4 amino acid peptides influence cell signaling, gene expression and aging-related cellular markers. | Bioregulator research remains mechanistic and should not be treated as clinical validation. |
| Mesenchymal stem cell aging | AED effects on gene-expression markers including IGF1, FOXO1, TERT, TNKS2 and NFκB in aging cell cultures. | Cell-culture findings should not be generalized into human anti-aging claims. |
| Fibroblast research | Cellular aging, extracellular matrix signaling, senescence-associated pathways and connective tissue models. | Fibroblast findings do not automatically prove cartilage repair or clinical tissue regeneration. |
| Cartilage and chondrocyte context | Cartilage matrix biology, chondrocyte signaling, collagen and proteoglycan-related pathways. | Cartilage pathway research should not be described as joint therapy or arthritis treatment. |
| Extracellular matrix research | Collagen, proteoglycan, matrix remodeling and tissue integrity models. | Matrix-related pathway data should remain research-only and model-specific. |
| Comparative peptide research | How AED compares with other short peptides and tissue-related peptides such as AEDG, KED, GHK-Cu, BPC-157 and TB-500. | Related peptide findings cannot be automatically transferred to Cartalax. |
Cartalax is often grouped with connective tissue, repair and short peptide bioregulator compounds, but its mechanism and evidence profile are distinct.
| Compound | Primary Research Pathway | How It Differs From Cartalax |
|---|---|---|
| Cartalax | Ala-Glu-Asp short peptide bioregulator research | Exploratory short tripeptide studied in gene-expression, connective tissue and matrix-related research contexts. |
| BPC-157 | Tissue repair, angiogenesis, gut and injury-model research | Much larger peptide with a different research pathway and broader repair-model literature. |
| TB-500 | Actin dynamics, cell migration and tissue-model research | Thymosin beta-4 fragment research category, not a short AED bioregulator peptide. |
| GHK-Cu | Copper peptide biology, collagen, extracellular matrix and wound-model research | Copper-binding tripeptide with a different metal-binding and matrix-research profile. |
| AHK-Cu | Copper peptide and dermal papilla / follicular research | Copper peptide category with a different sequence and research focus. |
| KPV | Alpha-MSH fragment and immune-inflammatory signaling research | Short tripeptide like Cartalax, but belongs to a different peptide-family and immune pathway context. |
| Epitalon | AEDG tetrapeptide, telomere and cellular aging research | Related short peptide category, but Epitalon is Ala-Glu-Asp-Gly, not Ala-Glu-Asp. |
| Pinealon | Short peptide neuroregulatory and cellular stress research | Different sequence and target context, mainly discussed in neuroregulatory research. |
Cartalax is a short AED tripeptide. BPC-157 and TB-500 are repair-model peptides. GHK-Cu and AHK-Cu are copper peptides. KPV is an immune-related tripeptide. Epitalon is an AEDG tetrapeptide. These compounds may all appear in tissue or aging research discussions, but they are not interchangeable.
Cartalax has a narrower evidence base than many well-known research peptides. The strongest public literature context comes from short peptide bioregulator studies, Ala-Glu-Asp research, human mesenchymal stem cell aging models and broader cartilage peptide research.
| Evidence Area | What the Literature Reports | Research Interpretation |
|---|---|---|
| AED gene-expression research | Human mesenchymal stem cell aging culture research studied Ala-Glu-Asp effects on IGF1, FOXO1, TERT, TNKS2 and NFκB gene expression. | Supports an AED gene-expression research context, not a clinical outcome claim. |
| Short peptide bioregulators | Reviews and related studies discuss short peptides as possible modulators of gene expression, differentiation and cellular aging markers. | Useful framework, but findings vary by peptide sequence and model. |
| Fibroblast and connective tissue models | Short peptide literature includes fibroblast aging and extracellular matrix-related research contexts. | Relevant to connective tissue biology, but not proof of cartilage repair. |
| Cartilage peptide research | Cartilage repair reviews describe peptide-based strategies involving chondroinductive peptides, scaffolds, matrix-targeting peptides and chondrocyte regulation. | Provides background for cartilage peptide research, but does not specifically validate Cartalax as a clinical cartilage therapy. |
| Database identity | Alanyl-glutamyl-aspartic acid is listed in PubChem with formula C12H19N3O8 and molecular weight 333.29 g/mol. | Supports identity and documentation review. |
| Clinical evidence gap | Publicly accessible Cartalax-specific human evidence remains limited compared with better-studied peptide categories. | Requires conservative language and careful separation from consumer claims. |
Cartalax is often promoted online with strong cartilage, joint and anti-aging language. A research-use-only page should avoid that framing and focus instead on verified identity, short peptide biology, gene-expression models and the limitations of the current evidence base.
The strongest scientific framing is conservative: Cartalax is a short synthetic tripeptide used to study Ala-Glu-Asp bioregulator biology, gene-expression patterns, connective tissue cell models and extracellular matrix-related pathways.
Because Cartalax is a short tripeptide with multiple naming conventions, quality evaluation should focus on compound identity, sequence confirmation, purity, lot-level traceability, analytical method, storage guidance and clear research-use-only labeling.
| Standard | Why It Matters |
|---|---|
| Batch-specific COA | Connects the material to lot-level analytical documentation. |
| Sequence confirmation | Supports confirmation that the material is Ala-Glu-Asp and not a related short peptide such as AEDG or KED. |
| Purity verification | Supports cleaner interpretation and reduces impurity-related confounding. |
| Identity confirmation | Helps verify the compound against formula, mass and sequence documentation. |
| Clear compound naming | Reduces confusion between Cartalax, AED, T-31, AEDG, KED and unrelated cartilage peptides. |
| Storage and handling guidance | Reduces avoidable degradation, moisture exposure and handling variability. |
| Research-use-only labeling | Keeps the material separated from consumer, supplement, joint, therapeutic, anti-aging or human-use positioning. |
These answers cover the most common Cartalax, Ala-Glu-Asp, AED, short peptide bioregulator and cartilage matrix research questions in 2026.
Cartalax is a short synthetic tripeptide commonly identified as Ala-Glu-Asp, AED or T-31. It is studied in short peptide bioregulator research involving gene-expression models, connective tissue cells, fibroblast biology and cartilage matrix-related pathways.
Cartalax is commonly described as Ala-Glu-Asp, which means alanine, glutamic acid and aspartic acid. Researchers should confirm sequence identity through supplier documentation and analytical testing.
The CAS number 205640-90-0 is commonly used in supplier references for Cartalax. PubChem lists the related alanyl-glutamyl-aspartic acid compound record under CID 87815447. Researchers should confirm identity using the COA, molecular formula, sequence and analytical method.
Cartalax is commonly associated with AED, the abbreviation for Ala-Glu-Asp. Researchers should still verify the exact sequence and analytical documentation because short peptide naming can vary across suppliers and publications.
Cartalax is studied in short peptide bioregulator research involving gene-expression patterns, mesenchymal stem cell aging models, fibroblast function, connective tissue biology, extracellular matrix signaling and cartilage-related experimental frameworks.
Cartalax should not be described as repairing cartilage. It is studied in cartilage matrix and connective tissue research contexts, but current evidence does not support treatment, joint-health, arthritis or cartilage-repair claims for research-use material.
Cartalax is a short Ala-Glu-Asp tripeptide studied in bioregulator and connective tissue models. BPC-157 and TB-500 are larger repair-model peptides with different structures, pathway contexts and research evidence profiles.
Cartalax is an Ala-Glu-Asp short peptide. GHK-Cu is a copper-binding tripeptide studied for copper peptide biology, collagen, extracellular matrix and wound-model research. They are not interchangeable.
No. Luxara Labs Cartalax is supplied strictly for laboratory research use only. It is not intended for human consumption, veterinary use, diagnostic use, therapeutic use, joint treatment, cosmetic use or anti-aging use.
Researchers should look for batch-specific COAs, purity documentation, sequence or identity confirmation, molecular reference information, lot numbers, storage guidance and research-use-only labeling.
These references support the Cartalax, Ala-Glu-Asp, AED, short peptide bioregulator, gene-expression, mesenchymal stem cell aging, fibroblast, extracellular matrix, cartilage peptide and research-use context discussed on this page.
Join our list and get an instant 10% discount code — valid for first-time buyers.
